New Zealand markets open in 2 hours 38 minutes
  • NZX 50

    11,382.56
    +60.85 (+0.54%)
     
  • NZD/USD

    0.6248
    -0.0014 (-0.23%)
     
  • ALL ORDS

    7,447.60
    +15.40 (+0.21%)
     
  • OIL

    76.28
    -1.66 (-2.13%)
     
  • GOLD

    1,754.00
    +8.40 (+0.48%)
     

Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks

Got $2,000? Buy These 2 Bear Market-Beating Growth Stocks

With the market down by more than 21% in 2022, we're officially in a bear market, and many investors are scrambling to protect themselves. AbbVie's (NYSE: ABBV) stock is up 9.9% this year, and with a bunch of recently reported clinical trial results and green lights from regulators, it isn't too surprising why. Most recently, on Sept. 10, it announced that a pair of its phase 3 trials of Skyrizi, a psoriatic arthritis drug that's already on the market, showed that the drug was performing favorably in long-term followup studies.